Navigation Links
Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers
Date:12/1/2009

tax specialists will grow substantially as tax issues for the industry become more complex.
  • More than half of the respondents said they are now being consulted early on by senior management in strategic business decisions, and thus have influence over the direction of the company. Still, 34 percent said they are consulted late in the game, and 9 percent of tax leaders said they are informed after the fact about strategic business decisions that have tax implications for the organization.
  • "To continue to deliver value to shareholders and society, pharmaceutical and life sciences companies must make strategic decisions about how they will drive innovation and profitability, but as they do so, each company's top tax executive needs a prominent 'seat at the C suite table,'" said Michael Swanick, global pharmaceutical and life sciences tax leader, PricewaterhouseCoopers. "Tax planning will be a critical consideration, not an afterthought, of long-term business plans to grow, buy, merge or sell and it will be one of the most important considerations in deciding where to locate IP, manufacturing and service delivery."

    Pharma 2020: Taxing times ahead - Which path will you take? is the fifth paper in the PricewaterhouseCoopers' Pharma 2020 series examining key forces reshaping the pharmaceutical marketplace. Focusing on the challenges and opportunities ahead from a tax perspective, the report identifies the following market forces making tax issues more complex.

    Economic and Government Pressure: Crackdown on Tax Havens

    The global recession has made tax authorities around the world hungry for new revenue sources to overcome growing budget deficits and potential new costs associated with healthcare reform initiatives. Governm
    '/>"/>

    SOURCE PricewaterhouseCoopers
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
    2. Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores
    3. Frost & Sullivan Award Underlines Cipla Medpros Status as Company of the Year in the South African Generic Pharmaceutical Market
    4. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
    5. iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering
    6. Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
    7. Pharmaceutical Institute Launches New Training Resource Focused on the Hospital Marketplace
    8. Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase
    9. Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference
    10. Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
    11. Isis Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... Summary GlobalData,s new ... provides key market data on the BRIC Gynecological ... of US dollars, volume (in units) and average ... Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and ...
    (Date:9/17/2014)... YORK , Sept. 17, 2014 /PRNewswire/ ... growth during the last decade due to ... natural calamities and technological advancements. This BCC ... within various segments of the ambulance and ... transportation equipment, blood and hemorrhage control devices, ...
    (Date:9/17/2014)... YORK , Sept. 17, 2014 Pomerantz ... PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") (NASDAQ: ... S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ... BioPharma and certain of its officers and/or directors have ... Act of 1934.  On September 17, ...
    Breaking Medicine Technology:BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2
    ... studies affirmed the clinical benefits of,ACTEMRA -, ... Phase III studies,showed that patients who suffer from ... achieved significant improvements in signs and,symptoms when treated ... compared with methotrexate alone. The final results of,both ...
    ... PTC124 Highlighted in Multiple Presentations at North ... N.J. and ORLANDO, Fla., Oct. 24 ... from a randomized,Phase 2a European study demonstrated ... statistically significant improvements,in the chloride channel function ...
    Cached Medicine Technology:ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 2ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 3ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 5ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 6PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 2PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 3PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 4PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 5PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients 6
    (Date:9/18/2014)... (PRWEB) September 18, 2014 According to the ... from eczema, with many of them being children. In fact, ... diagnosed as babies and children. The millions of children who ... be brought on by eczema. A new book has been ... they are and to find relief from the condition over ...
    (Date:9/18/2014)... (PRWEB) September 18, 2014 SpineFrontier ... team and surgeon partners in Less Exposure Surgery ... SpineFrontier, Tamara authored an extensive education curriculum and ... Masters in Science in Organizational Leadership, and has ... for eleven years. Bringing her to the team ...
    (Date:9/18/2014)... 18, 2014 First Choice Emergency ... rooms in the United States, named Douglas J. Harrison, ... City-Lakes facility. , “We are pleased to welcome ... director of our new Missouri City-Lakes facility,” said Dr. ... Emergency Room. , Dr. Harrison received his undergraduate ...
    (Date:9/18/2014)... N-Zyme Scientifics LLC achieved a major developmental milestone ... mere 8 months after company startup. Its novel product ... enzyme used in the “Biologics” industry for discovery and ... pathology on Mass Spec devices. PRIME™ is being sold ... market (PNGase F PRIMETM). N-Zyme is currently evaluating ...
    (Date:9/17/2014)... September 18, 2014 Recently, BambooIndustry.com, an outstanding ... of bamboo floorings . There are more than 1000 ... has launched a big promotion for these useful items. Each ... 30 % off. , “We are very proud to ... to say, all these items are made with natural materials ...
    Breaking Medicine News(10 mins):Health News:New Book Helps Millions of Children Deal With The Emotional Pains of Suffering From Eczema 2Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:More Than 1000 Items Added To BambooIndustry.com’s Bamboo Flooring Collection 2
    ... a newly developed drug, which is aimed at a particular ... tumour growth, is active in patients with advanced cancers and, ... The drug, ACE-041, targets a different molecular pathway to ... treat cancer. Results from a phase I clinical ...
    ... surgery should receive a risk assessment before their procedure ... in the legs or lungs, according to research at ... that 1 in 9 patients at highest risk based ... clot-preventing medications after surgery. Published in the November ...
    ... into mice with metastatic melanoma has resulted in permanent ... cancer, according to an article to be published in ... Clinical Investigation . The online version is now available. ... modified lentivirus to introduce a potent anti-melanoma T cell ...
    ... federal agencies recently cosponsored a set of expert work ... to psychological adjustment and traumatic brain injury (TBI). ... behavioral neuroscience at Boston University School of Medicine, chaired ... Dr. Kaloupek,s work at the National Center for PTSD ...
    ... of six national participants in a pilot study that ... families have a smoother care experience and better outcomes ... to reliably adhere to best practice standards. The ... the Society of Thoracic Surgeons (STS) will study clinician ...
    ... have been stymied for years over the fact that people ... response to the pathogen antibodies that turn out to ... Medical Center can explain why: Some of the earliest and ... the virus until after it,s already invaded a healthy cell. ...
    Cached Medicine News:Health News:Researchers find new target for stopping tumors developing their own blood supply 2Health News:Researchers find new target for stopping tumors developing their own blood supply 3Health News:Assessment tool predicts blood clot risk after plastic surgery 2Health News:Assessment tool predicts blood clot risk after plastic surgery 3Health News:Gene therapy for metastatic melanoma in mice produces complete remission 2Health News:Researchers identify PTSD measures for use in traumatic brain injury research 2Health News:Lung cancer patients are the centerpiece for Northwestern medicine quality of care study 2Health News:Why so many antibodies fail to protect against HIV infection 2
    ... When it comes to ventral hernia repair, ... While a hernia is often best treated with ... concern about the risk of bowel adhesions to ... mesh, an innovative product designed to meet the ...
    ... dual-sided ePTFE mesh designed for ventral hernia repair. ... to minimize visceral attachment to the prosthesis. On ... to promote tissue growth. This ingrowth side has ... is nearly equivalent to polypropylene mesh. Bard Dulex ...
    ... Since its introduction in 1958, Bard mesh ... other products are compared. Bard mesh was ... first developed the "tension-free" hernia repair many ... "a safe and ideal" substance for permanent ...
    ... Modified Kugel patch repair is a minimally ... through a small 4-6 cm incision and ... repair performed through an open, anterior approach ... regional anesthesia.,The Modified Kugel patch is a ...
    Medicine Products: